Search Results - "Milan, Lukas"

Inflammatory bowel disease as a risk factor for colorectal cancer by Lukas, Milan

“…Patients with long-term inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's colonic disease (CD) have an increased risk of colorectal…”
Get more information

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease by Sandborn, William J, Feagan, Brian G, Rutgeerts, Paul, Hanauer, Stephen, Colombel, Jean-Frédéric, Sands, Bruce E, Lukas, Milan, Fedorak, Richard N, Lee, Scott, Bressler, Brian, Fox, Irving, Rosario, Maria, Sankoh, Serap, Xu, Jing, Stephens, Kristin, Milch, Catherine, Parikh, Asit

“…In this 52-week randomized trial, the α 4 β 7 integrin antibody vedolizumab was effective in treating Crohn's disease. The incidence of serious adverse events…”
Get full text

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy by Sands, Bruce E, Sandborn, William J, Van Assche, Gert, Lukas, Milan, Xu, Jing, James, Alexandra, Abhyankar, Brihad, Lasch, Karen

“…Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn's disease (CD). Aims of this study were to…”
Get full text

Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project by Cleynen, Isabelle, González, Juan R, Figueroa, Carolina, Franke, Andre, McGovern, Dermot, Bortlík, Martin, Crusius, Bart J A, Vecchi, Maurizio, Artieda, Marta, Szczypiorska, Magdalena, Bethge, Johannes, Arteta, David, Ayala, Edgar, Danese, Silvio, van Hogezand, Ruud A, Panés, Julian, Peña, Salvador Amado, Lukas, Milan, Jewell, Derek P, Schreiber, Stefan, Vermeire, Severine, Sans, Miquel

“…Through genome-wide association scans and meta-analyses thereof, over 70 genetic loci (Crohn's disease (CD) single nucleotide polymorphisms (SNPs)) are…”
Get more information

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis by Vermeire, Séverine, Lukáš, Milan, Magro, Fernando, Adsul, Shashi, Lindner, Dirk, Rosario, Maria, Roth, Jeannine, Danese, Silvio

“…Abstract Background and Aims Vedolizumab was shown to be safe and effective for the treatment of Crohn’s disease [CD] and ulcerative colitis [UC] in the GEMINI…”
Get full text

Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics? by Malickova, Karin, Kratka, Zuzana, Luxova, Stepanka, Bortlik, Martin, Lukas, Milan

“…Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has spread worldwide triggering a pandemic during…”
Get full text

Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial by Hanauer, Stephen B., Sandborn, William J., Rutgeerts, Paul, Fedorak, Richard N., Lukas, Milan, MacIntosh, Donald, Panaccione, Remo, Wolf, Douglas, Pollack, Paul

“…Background & Aims: Tumor necrosis factor blockade has been shown to be an effective treatment strategy in Crohn’s disease (CD). Adalimumab is a human…”
Get full text

Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn's disease and ulcerative colitis by Dryahina, Kseniya, Smith, David, Bortlík, Martin, Machková, Naděžda, Lukáš, Milan, Španěl, Patrik

“…A study has been carried out on the volatile organic compounds (VOCs) in the exhaled breath of patients suffering from inflammatory bowel disease (IBD),…”
Get more information

The relationship between serum bilirubin and Crohn's disease by Leníček, Martin, Duricová, Dana, Hradsky, Ondrej, Dušátková, Petra, Jirásková, Alena, Lukáš, Milan, Nachtigal, Petr, Vítek, Libor

“…The oxidative stress is thought to play an important role in Crohn's disease (CD). As serum bilirubin represents the major endogenous antioxidant, this article…”
Get full text

Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study by Rob, Filip, Schierova, Dagmar, Stehlikova, Zuzana, Kreisinger, Jakub, Roubalova, Radka, Coufal, Stepan, Mihula, Martin, Jackova, Zuzana, Kverka, Miloslav, Thon, Tomas, Kostovcikova, Klara, Bajer, Lukas, Drastich, Pavel, Hercogova, Jana Tresnak, Novakova, Michaela, Kolar, Martin, Vasatko, Martin, Lukas, Milan, Tlaskalova-Hogenova, Helena, Jiraskova Zakostelska, Zuzana

“…Ustekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn's disease (CD) who did not respond to anti-TNF treatment. To…”
Get full text

Biosimilars: A Multidisciplinary Perspective by Khraishi, Majed, MB, BCh, FRCPC, Stead, David, GPhC, MRPharmS, DMS, Lukas, Milan, MD, PhD, Scotte, Florian, MD, PhD, Schmid, Holger, MD, MSc

“…Abstract A biosimilar is an officially regulated and approved copy of an originator biologic therapy. Improved affordability and consequent wider patient…”
Get full text

Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation by Bortlik, Martin, Duricova, Dana, Machkova, Nadezda, Hruba, Veronika, Lukas, Martin, Mitrova, Katarina, Romanko, Igor, Bina, Vladislav, Malickova, Karin, Kolar, Martin, Lukas, Milan

“…Background: Discontinuation of anti-TNF therapy in patients with inflammatory bowel diseases (IBD) in remission remains a controversial issue. The aims of our…”
Get full text

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis by Farkas, Klaudia, Rutka, Mariann, Golovics, Petra A., Végh, Zsuzsanna, Lovász, Barbara D., Nyári, Tibor, Gecse, Krisztina B., Kolar, Martin, Bortlik, Martin, Duricova, Dana, Machkova, Nadezda, Hruba, Veronika, Lukas, Martin, Mitrova, Katarina, Malickova, Karin, Bálint, Anita, Nagy, Ferenc, Bor, Renáta, Milassin, Ágnes, Szepes, Zoltán, Palatka, Károly, Lakatos, Péter L., Lukas, Milan, Molnár, Tamás

“…Introduction: CT-P13 is the first biosimilar to infliximab that has been approved for the same indications as its originator infliximab. No data are available…”
Get full text

Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD by Coufal, Stepan, Kverka, Miloslav, Kreisinger, Jakub, Thon, Tomas, Rob, Filip, Kolar, Martin, Reiss, Zuzana, Schierova, Dagmar, Kostovcikova, Klara, Roubalova, Radka, Bajer, Lukas, Jackova, Zuzana, Mihula, Martin, Drastich, Pavel, Tresnak Hercogova, Jana, Novakova, Michaela, Vasatko, Martin, Lukas, Milan, Tlaskalova-Hogenova, Helena, Jiraskova Zakostelska, Zuzana

“…Background. Tumor necrosis factor-alpha (TNF-α) agonists revolutionized therapeutic algorithms in inflammatory bowel disease (IBD) management. However,…”
Get full text

Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease by Malíčková, Karin, Ďuricová, Dana, Bortlík, Martin, Hind’oš, Miroslav, Machková, Naděžda, Hrubá, Veronika, Lukáš, Martin, Zima, Tomáš, Lukáš, Milan

“…CT-P13 is a biosimilar drug of reference infliximab and is approved in some countries for use in some indications for which reference infliximab is approved,…”
Get full text

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study by Mitrova, Katarina, Pipek, Barbora, Bortlik, Martin, Bouchner, Ludek, Brezina, Jan, Douda, Tomas, Drasar, Tomas, Drastich, Pavel, Falt, Premysl, Klvana, Pavel, Leksa, Vaclav, Novotny, Ales, Svoboda, Pavel, Skorpik, Jan, Ulbrych, Jan, Veinfurt, Marek, Zborilova, Blanka, Lukas, Milan, Duricova, Dana

“…Background: Vedolizumab demonstrated different placental pharmacokinetics than other immunoglobulin G1 antibodies, leading to lower drug levels in cord blood…”
Get full text

Development and Validation of a Patient-reported Score to Screen for Mucosal Inflammation in Inflammatory Bowel Disease by de Jong, Marin J, Roosen, Danielle, Degens, Juliette H R J, van den Heuvel, Tim R A, Romberg-Camps, Marielle, Hameeteman, W, Bodelier, Alexander G L, Romanko, Igor, Lukas, Milan, Winkens, Bjorn, Markus, Tineke, Masclee, Ad A M, van Tubergen, Astrid, Jonkers, Daisy M A E, Pierik, Marie J

“…Abstract Background and Aims Patient-reported outcome measures [PROMs] assessing inflammatory bowel disease [IBD] activity are of interest for monitoring in…”
Get full text

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy by Reiss, Zuzana, Rob, Filip, Kolar, Martin, Schierova, Dagmar, Kreisinger, Jakub, Jackova, Zuzana, Roubalova, Radka, Coufal, Stepan, Mihula, Martin, Thon, Tomas, Bajer, Lukas, Novakova, Michaela, Vasatko, Martin, Kostovcikova, Klara, Galanova, Natalie, Lukas, Milan, Kverka, Miloslav, Tresnak Hercogova, Jana, Tlaskalova-Hogenova, Helena, Jiraskova Zakostelska, Zuzana

“…Crohn's disease (CD) and ulcerative colitis (UC) are two forms of inflammatory bowel disease (IBD), where the role of gut but not skin dysbiosis is well…”
Get full text

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases by Park, Sang Hyoung, Park, Jae Cheol, Lukas, Milan, Kolar, Martin, Loftus, Edward V.

“…The inflammatory bowel diseases (IBD), which consist of Crohn’s disease and ulcerative colitis, are chronic, incurable immunemediated inflammatory disorders of…”
Get full text

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy by Schierova, Dagmar, Roubalova, Radka, Kolar, Martin, Stehlikova, Zuzana, Rob, Filip, Jackova, Zuzana, Coufal, Stepan, Thon, Tomas, Mihula, Martin, Modrak, Martin, Kverka, Miloslav, Bajer, Lukas, Kostovcikova, Klara, Drastich, Pavel, Hercogova, Jana, Novakova, Michaela, Vasatko, Martin, Lukas, Milan, Tlaskalova-Hogenova, Helena, Jiraskova Zakostelska, Zuzana

“…Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system…”
Get full text